89bio (NASDAQ:ETNB) has completed enrollment in ENLIVEN, the Phase 2b trial of pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).
The ENLIVEN is a Phase 2b trial in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients with fibrosis stage 2 or 3, The study has enrolled around 219 patients.
The enrolled patients will receive either one of two weekly doses (15mg or 30mg) or an every two-week dose (44mg) of pegozafermin in a liquid formulation or placebo for 24 weeks.
Hank Mansbach, Chief Medical Officer, said, “The impressive pace of enrollment is a testament to both the high level of engagement by our clinical trial sites and our team’s strategic execution and brings us one step closer to addressing the need for new treatment options for patients suffering from NASH. We see this as a significant milestone in the pegozafermin clinical program and, building on this momentum.”
89bio expects to report topline data from ENLIVEN in the first quarter of 2023.
Pegozafermin is a fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life.
Price Action : 89bio shares are trading around 7 percent higher at $5.08 on Thursday at the time of publication.
